Analysts Cool on Exelon After Q1 Miss

EXC heads into mid-May with a notable mismatch between where the Street is and where the stock trades.

The analyst community has turned meaningfully more cautious over the past month. The wave started on April 17, when Barclays downgraded from Overweight to Equal-Weight and BMO Capital cut from Outperform to Market Perform — both trimming targets at the same time. Jefferies followed on April 20, downgrading to Hold from Buy and pulling its target to $50 from $55. Truist initiated coverage the same week at Hold. The direction of travel is clear: the previously constructive camp has stepped back. The mean price target now sits at $50.00, about 11% above the current $44.98 close — but that consensus includes targets set before the recent sell-off. Keybanc, which already held an Underweight, cut its target again this week to $41, below where EXC trades today. Morgan Stanley maintained Equal-Weight in late April while nudging its target down to $55. In short, the Street has gone from broadly bullish to predominantly neutral-to-cautious, with at least one firm pointing below the current price.

The valuation reset is visible in the numbers. The P/E multiple has contracted roughly 7% over the past 30 days, now at 15.4x. The price-to-book ratio has fallen nearly 8% over the same period to 1.48x. Both moves reflect the stock's 7.4% pull-back over the month. The earnings yield and EV/EBITDA (9.7x) are drifting back toward the middle of their recent range — suggesting the de-rating has occurred, but not that EXC looks dramatically cheap. The dividend score ranks in the 93rd percentile, underpinning yield-focused ownership, with a forward yield running near 3.8%. That income floor has likely cushioned selling pressure, but it hasn't reversed it.

The options market tells a more defensive story than the headline short interest would suggest. The put/call ratio is running at 0.61 — well above its 20-day average of 0.51 — sitting roughly one standard deviation above that recent norm. The PCR has been elevated all month: it jumped sharply at the start of May and has held the higher range. That marks a clear pivot from April, when PCR was consistently below 0.45. Options traders have been buying more downside protection since the Q1 earnings print on May 6, which sent the stock down 3.8% on the day.

Short interest, by contrast, has actually retreated. SI dropped sharply to 3.6% of free float — down from around 4.2% just a week ago, a 13% fall in positions week-on-week. The ORTEX short score has also eased, falling from roughly 42 to 39.6 over the past week. Borrow remains cheap at 0.46% annually, and availability is wide, so there is no squeeze dynamic in the lending market. Shorts unwinding into the post-earnings dip is the more plausible read. Peers tracked similar weekly weakness: FE fell 2.6% on the week, PPL dropped 2.7%, and AEP declined 3.7%, confirming this was a sector-wide move rather than an EXC-specific story.

The bulls point to EXC's transmission footprint commanding a FERC ROE of around 10.5%, and ComEd's year-over-year earnings growth supported by regulatory timing and recoverable assets. The bear case — already playing out in the stock — centres on rate case risk, a potentially trimmed capex programme, and sensitivity to interest rates at a time when rates remain elevated. With the next earnings event not until July 29, the stock now trades on the pace of regulatory clarity and whether the analyst community stabilises its target revisions or continues trimming. The RSI sits near 39, territory that in utility names often reflects a stock waiting for a catalyst rather than one in freefall.

The key watch point is whether further target cuts follow from firms that have so far only trimmed, not downgraded.